DBGen is a company that is devoted to genetic testing of hereditary eye diseases in a way that combines quality, diagnostic efficiency and engagement between the patient, the ophthalmologist and the companies requiring its services.

At DBGen we offer a quality, reliable and affordable genetic diagnosis that secures the clinical diagnosis and can guide the patient toward the right emerging therapies for genetic eye diseases. The genetic diagnosis can be used to identify asymptomatic relatives who carry the genetic defect, and is an essential step to provide genetic counseling.


  • Area of Activity
  • Research Centers
  • Rares diseases
  • Oftalmology
  • Genomics
  • Genetic diseases
  • DNA tests
  • Bioinformatics
  • Company type
  • Public and Private Organizations - Non Profit Centers - Medical Research Facilities
  • Health Biotechnology
  • Technology Services
Headquarter
Avenida Diagonal 643, Edificio Prevosti planta 2
Barcelona, Barcelona 08028, ES
P: 934021034
E:info@dbgen.org

DBGen is a company that is devoted to genetic testing of hereditary eye diseases in a way that combines quality, diagnostic efficiency and engagement between the patient, the ophthalmologist and the companies requiring its services.

At DBGen we offer a quality, reliable and affordable genetic diagnosis that secures the clinical diagnosis and can guide the patient toward the right emerging therapies for genetic eye diseases. The genetic diagnosis can be used to identify asymptomatic relatives who carry the genetic defect, and is an essential step to provide genetic counseling.

Roser Gonzàlez-Duarte: Founder and Director

Roser received her PhD in Biology (Molecular Genetics) from the University of Barcelona and did her postdoctoral training at the University of Edinburgh. She is Full Professor in Genetics at the Universitat of Barcelona. She has been deeply involved in the tuition of molecular genetics to faculty students and has gained recognition as the Chairman of the Department of Genetics and Director of the Masters’ degree in Biotechnology. She was elected President of the Spanish Genetic Society. For over the last two decades she has led a research team devoted to the study of the genetic bases of inherited retinal disorders. She is widely recognised for her contributions on novel retinal disease gene identification, development of diagnostic chips, mutation identification associated with hereditary retinal disorders and, recently, the development of highly specific and comprehensive gene panels and exome sequencing strategies for high diagnostic yield of ocular pathologies. She is CEO and co-founder of DBGen.

Gemma Marfany: Founder and Associate Director

Gemma is an Associate Professor of Genetics of the University of Barcelona (UB) Spain, specialized in molecular and human genetics, human genome, genetic diagnosis and gene therapy. Her career as human molecular geneticist is the result of her scientific development in Barcelona, Edinburgh and Oxford Universities. She is currently principal investigator of a research group focused on the genetic diagnosis of inherited visual disorders and the functional analysis of candidate genes in cell and animal models. She contributes to scientific divulgation weekly and is also involved in several Committees of Bioethics. She is head of the CIBERER U-718 unit, and member of IBUB (Institut de Biomedicina de la UB) and the Observatory of Bioethics and Law (OBD UB). She has currently published more than 100 articles in international peer-reviewed journals, including books and book chapters. She is a co-founder and CSO of DBGen.

At DBGen we diagnose every inherited eye disease, syndromic and non-syndromic, primarily those affecting the retina.

There are over 150 diseases that affect eyesight. Most are difficult to diagnose clinically because they exhibit similar symptoms. There are over 260 genes known to cause retinal dystrophies, and over 500 if all eye diseases are considered.


Stemming from an academic background, which facilitates the incorporation of conceptual, methodological and bioinformatic improvements.

We aim to contribute to the understanding of the molecular basis of visual disorders and inspire novel therapeutic approaches. Therefore, our research is also focused on the generation of animal models and cell lines that mimic the effects associated to the pathogenic variants identified in retinal degeneration-causing genes.

Many visual disorders are rare and don’t get enough attention. For us, it’s key to have a close relationship with the patient and ophthalmologist to answer all their questions and give complete feedback about the genetic diagnosis fulfilled and its implications.

Patients

Ophtalmologists

Patients associations

Ophtalmological centers

Pharmaceutical and biotech companies

DBGen Ocular Genomics